GPC Biotech, Inc. To Present At Two Upcoming Conferences
Published: Oct 30, 2006
MARTINSRIED/MUNICH, Germany, Oct. 30 /PRNewswire-FirstCall/ -- U.S. Research and Development Facilities in Waltham, Mass., and Princeton, N.J. -- GPC Biotech AG today announced that the Company will give a corporate presentation at the upcoming Rodman & Renshaw 8th Annual Healthcare Conference in New York, NY, as well as at the Cowen & Co. 7th Global Health Care Conference in London.
The presentation at the Rodman & Renshaw 8th Annual Healthcare Conference is scheduled for Monday, November 6, 2006 at 10:15 AM EST at the New York Palace Hotel in New York.
The presentation at the Cowen & Co. 7th Global Health Care Conference will take place on Tuesday, November 7, 2006 at 3:05 PM GMT at The Landmark Hotel in London.
The company presentations at both conferences will be webcast live and will be accessible through the GPC Biotech Web site at http://www.gpc-biotech.com. A replay will also be available via the Web site.
GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company's lead product candidate -- satraplatin -- has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company's Web site at http://www.gpc-biotech.com.
For further information, please contact: GPC Biotech AG Martin Braendle Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 firstname.lastname@example.org In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 781-890-9007 X267 email@example.comGPC Biotech AG
CONTACT: Martin Braendle, Director, Investor Relations & CorporateCommunications, +49 (0)89 8565-2693, firstname.lastname@example.org, or Laurie Doyle,Director, Investor Relations & Corporate Communications, +1-781-890-9007,ext. 267, email@example.com, both of GPC Biotech AG
Web site: http://www.gpc-biotech.com/